(NASDAQ: KYNB) Kyntra Bio's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 12.05%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 32.95%.
Kyntra Bio's earnings in 2026 is -$17,287,000.On average, 7 Wall Street analysts forecast KYNB's earnings for 2026 to be -$35,780,807, with the lowest KYNB earnings forecast at -$53,224,093, and the highest KYNB earnings forecast at -$19,986,676. On average, 7 Wall Street analysts forecast KYNB's earnings for 2027 to be -$40,714,904, with the lowest KYNB earnings forecast at -$65,289,808, and the highest KYNB earnings forecast at -$17,265,086.
In 2028, KYNB is forecast to generate -$41,599,016 in earnings, with the lowest earnings forecast at -$77,553,973 and the highest earnings forecast at -$13,097,651.